Cristina Papayannidis

List of Publications by Year in Descending Order

172 papers	2,984 citations	31 h-index	52 g-index
185 ext. papers	3,560 ext. citations	3.8 avg, IF	4.33 L-index

#	Paper	IF	Citations
172	Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters.. *Frontiers in Immunology*, **2021**, 12, 804988	8.4	0
171	Real-World Multicenter Experience in Tumor Debulking Prior to Blinatumomab Administration in Adult Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia.. *Frontiers in Oncology*, **2021**, 11, 804714	5.3	2
170	INCB84344-201: Ponatinib and steroids in frontline therapy of unfit patients with Ph+ acute lymphoblastic leukemia. *Blood Advances*, **2021**,	7.8	5
169	Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study. *European Journal of Cancer*, **2021**, 146, 107-114	7.5	13
168	Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a. *Biomedicines*, **2021**, 9,	4.8	3
167	Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant. *Hematological Oncology*, **2021**, 39, 580-583	1.3	1
166	Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations. *Leukemia*, **2021**, 35, 2813-2826	10.7	3
165	Adrenomedullin Expression Characterizes Leukemia Stem Cells and Associates With an Inflammatory Signature in Acute Myeloid Leukemia. *Frontiers in Oncology*, **2021**, 11, 684396	5.3	0
164	Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study. *Leukemia*, **2021**, 35, 62-74	10.7	34
163	Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia. *British Journal of Haematology*, **2021**, 193, 271-279	4.5	1
162	Loss of PALB2 predicts poor prognosis in acute myeloid leukemia and suggests novel therapeutic strategies targeting the DNA repair pathway. *Blood Cancer Journal*, **2021**, 11, 7	7	2
161	Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia.. *Cancer Medicine*, **2021**,	4.8	2
160	MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia. *European Journal of Haematology*, **2020**, 105, 47-55	3.8	1
159	A Three-Gene Immune Signature Including IDO1, BIN1 and PLXNC1 Predicts Survival in Acute Myeloid Leukemia. *Blood*, **2020**, 136, 35-36	2.2	0
158	Hedgehog Pathway Inhibitors: A New Therapeutic Class for the Treatment of Acute Myeloid Leukemia. *Blood Cancer Discovery*, **2020**, 1, 134-145	7	15
157	Acute Myeloid Leukemia Mutations: Therapeutic Implications. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	11
156	Low-dose cytarabine with or without glasdegib in newly diagnosed patients with acute myeloid leukemia: Long-term analysis of a phase 2 randomized trial.. *Journal of Clinical Oncology*, **2019**, 37, 7010-7010	2.3	3

155	Blinatumomab is safe and effective in relapsed and MRD-positive B-ALL CD19+ patients: The Bologna Compassionate Program Experience.. *Journal of Clinical Oncology*, **2019**, 37, e18522-e18522	2.2	
154	Vascular and Parenchymal Alterations of the Liver and Liver Surveillance in Patients Who Received Inotuzumab Ozogamicin As the Standard of Care for Relapse/Refractory Acute Lymphoblastic Leukemia. *Blood*, **2019**, 134, 1343-1343	2.2	
153	Treatment of Adults with Minimal Residual Disease (MRD) Positive Acute Lymphoblastic Leukemia with Blinatumomab in a Real-World Setting: Results from the Neuf Study. *Blood*, **2019**, 134, 2624-2624	2.2	
152	Synergism Through WEE1 and CHK1 Inhibition in Acute Lymphoblastic Leukemia. *Cancers*, **2019**, 11,	6.6	9
151	Identification of Two Mutations Compromising Protein Stability and Methylation Capacity in Acute Myeloid Leukemia. *Journal of Oncology*, **2019**, 2019, 5985923	4.5	1
150	Novel and Rare Fusion Transcripts Involving Transcription Factors and Tumor Suppressor Genes in Acute Myeloid Leukemia. *Cancers*, **2019**, 11,	6.6	11
149	Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery. *Cancer*, **2019**, 125, 712-725	6.4	33
148	Chromothripsis in acute myeloid leukemia: biological features and impact on survival. *Leukemia*, **2018**, 32, 1609-1620	10.7	50
147	Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial. *American Journal of Hematology*, **2018**, 93, 655-663	7.1	18
146	SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis. *Leukemia*, **2018**, 32, 139-148	10.7	17
145	Low-Dose Anti-T Lymphoglobulin as Prophylaxis for Graft-versus-Host Disease in Unrelated Donor Transplantations for Acute Leukemias and Myelodysplastic Syndromes. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 2450-2458	4.7	6
144	Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia. *Journal of Hematology and Oncology*, **2018**, 11, 99	22.4	24
143	Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia. *Annals of Hematology*, **2018**, 97, 1767-1774	3	9
142	Leukemia cutis in a Ph+ ALL patient treated with ponatinib. *Giornale Italiano Di Dermatologia E Venereologia*, **2018**, 153, 730-731	0.8	
141	A New Gene Expression Profile Signature CRLF2 Overexpression Based Identifies Novel Adult "Triple Negative" Acute Lymphoblastic Leukemia Subgroups. *Blood*, **2018**, 132, 5284-5284	2.2	
140	Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia. *BMC Cancer*, **2018**, 18, 1117	4.8	10
139	The Italian Mastocytosis Registry: 6-year experience from a hospital-based registry. *Future Oncology*, **2018**, 14, 2713-2723	3.6	7
138	Epigenetically induced ectopic expression of UNCX impairs the proliferation and differentiation of myeloid cells. *Haematologica*, **2017**, 102, 1204-1214	6.6	6

137	The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report. *BMC Cancer*, **2017**, 17, 523	4.8	0
136	Clinical and experimental efficacy of gemtuzumab ozogamicin in core binding factor acute myeloid leukemia. *Hematology Reports*, **2017**, 9, 7029	0.9	13
135	Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study. *Journal of Clinical Oncology*, **2017**, 35, 1795-1802	2.2	264
134	Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis. *Nature Communications*, **2017**, 8, 593	17.4	104
133	Chromothripsis in acute myeloid leukemia: biological features and impact on survival. *Leukemia*, **2017**,	10.7	3
132	First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. *Blood*, **2017**, 130, 99-99	2.2	47
131	Prognostic significance of alterations of pathways regulating autophagy in acute myeloid leukemia.. *Journal of Clinical Oncology*, **2017**, 35, 7038-7038	2.2	1
130	Copy number variants signature in two patients with relapsed acute promyelocytic leukemia.. *Journal of Clinical Oncology*, **2017**, 35, e23207-e23207	2.2	
129	Microarray analysis to identifiy novel copy number alterations in acute myeloid leukemia.. *Journal of Clinical Oncology*, **2017**, 35, 11622-11622	2.2	
128	Deficient necroptosis pathway as a negative prognostic factor in acute myeloid leukemia.. *Journal of Clinical Oncology*, **2017**, 35, 11611-11611	2.2	
127	Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML. *Expert Opinion on Pharmacotherapy*, **2016**, 17, 2479-2486	4	3
126	Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities. *Genes Chromosomes and Cancer*, **2016**, 55, 375-88	5	3
125	Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients. *Clinical Cancer Research*, **2016**, 22, 1914-21	12.9	88
124	Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients. *Leukemia*, **2016**, 30, 1615-9	10.7	11
123	Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives. *Annals of Hematology*, **2016**, 95, 681-93	3	33
122	Ex-Vivo Drug Response Profiling for Precision Medicine Approaches in Acute Myeloid Leukemia with the Open Microwell Microfluidic Platform. *Blood*, **2016**, 128, 1675-1675	2.2	3
121	Aggressive Aneuploid Acute Myeloid Leukemia Is Dependent on Alterations of P53, Gain of APC and PLK1 and Loss of RAD50. *Blood*, **2016**, 128, 1702-1702	2.2	1
120	Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients. *Oncotarget*, **2016**, 7, 12951-61	3.3	24

119	Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients. *Oncotarget*, **2016**, 7, 21982-90	3.3	39
118	Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia. *Oncotarget*, **2016**, 7, 32532-42	3.3	58
117	Pharmacological interaction and side effects in oncohaematology: a retrospective observational study.. *Journal of Clinical Oncology*, **2016**, 34, e18235-e18235	2.2	
116	Impact on survival of catastrophic karyotype events in 101 consecutive acute myeloid leukemia (AML) patients: High risk karyotype and chromothripsis.. *Journal of Clinical Oncology*, **2016**, 34, 7044-7044	2.2	
115	Survival analysis of 409 consecutive patients with newly diagnosed acute myeloid leukemia treated with intensive induction therapy, with or without the addition of gemtuzomab-ozagomicin (GO).. *Journal of Clinical Oncology*, **2016**, 34, 7043-7043	2.2	
114	Survival and outcome data observed in 98 patients affected by acute myeloid leukemia undergoing chemotherapy consolidation courses treatment followed by autologous bone marrow transplantation (auto-BMT).. *Journal of Clinical Oncology*, **2016**, 34, e18520-e18520	2.2	
113	Survival analysis of patients carrying different FLT3 mutations (internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations) in 459 consecutive non M3 newly diagnosed acute myeloid leukemia (AML).. *Journal of Clinical Oncology*, **2016**, 34, e18521-e18521	2.2	
112	The QNext-in-CmlQStudy: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy. *Blood*, **2016**, 128, 3097-3097	2.2	
111	Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations. *Blood*, **2016**, 128, 1678-1678	2.2	
110	Alterations of BRCA1 and PALB2 Define a Novel Class of Complex-Karyotype AML with a Very Bad Prognosis. *Blood*, **2016**, 128, 1677-1677	2.2	
109	Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML). *Blood*, **2016**, 128, 1679-1679	2.2	
108	Mine the Stability of the G2/M Checkpoint to Break Down Acute Lymphoblastic Leukemia Defenses Against Antineoplastic Drugs. *Blood*, **2016**, 128, 2808-2808	2.2	
107	The Genomic and Transcriptomic Landscape of Systemic Mastocytosis. *Blood*, **2016**, 128, 3136-3136	2.2	1
106	Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia. *Oncotarget*, **2016**, 7, 53377-53391	3.3	32
105	FGFR1 and KAT6A rearrangements in patients with hematological malignancies and chromosome 8p11 abnormalities: biological and clinical features. *American Journal of Hematology*, **2016**, 91, E14-6	7.1	2
104	Optimized pipeline of MuTect and GATK tools to improve the detection of somatic single nucleotide polymorphisms in whole-exome sequencing data. *BMC Bioinformatics*, **2016**, 17, 341	3.6	60
103	Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients. *American Journal of Hematology*, **2016**, 91, 692-9	7.1	31
102	Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up. *American Journal of Hematology*, **2015**, 90, 515-23	7.1	38

101	A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. *Blood Cancer Journal*, **2015**, 5, e350	7	79
100	Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study. *Lancet Haematology,the*, **2015**, 2, e339-46	14.6	86
99	In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia. *Journal of Hematology and Oncology*, **2015**, 8, 125	22.4	24
98	IL-17/IL-10 double-producing T cells: new link between infections, immunosuppression and acute myeloid leukemia. *Journal of Translational Medicine*, **2015**, 13, 229	8.5	13
97	The Wee1 Inhibitor, MK-1775, Sensitizes Leukemic Cells to Different Antineoplastic Drugs Interfering with DNA Damage Response Pathway. *Blood*, **2015**, 126, 1276-1276	2.2	2
96	RNA Sequencing Reveals Novel and Rare Fusion Transcripts in Acute Myeloid Leukemia. *Blood*, **2015**, 126, 3627-3627	2.2	1
95	Genome-Wide Molecular Portrait of Aggressive Systemic Mastocytosis and Mast Cell Leukemia Depicted By Whole Exome Sequencing and Copy Number Variation Analysis. *Blood*, **2015**, 126, 4085-4085	2.2	1
94	Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients. *Oncotarget*, **2015**, 6, 31284-94	3.3	15
93	Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients. *Blood*, **2015**, 126, 3198-3198	2.2	
92	Genomic-Wide Analysis By High Resolution SNP Array Identifies Novel Genomic Alteration in Acute Myeloid Leukemia. *Blood*, **2015**, 126, 2600-2600	2.2	
91	Novel Genomic Patterns of Metabolic Remodeling in Acute Myeloid Leukemia. *Blood*, **2015**, 126, 3837-3837	2.2	
90	Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia. *Blood*, **2015**, 126, 2513-2513	2.2	
89	Clustering Adult ACUTE Lymphoblastic Leukemia (ALL) Philadelphia Negative (Ph-) By Whole Exome Sequencing (WES) Analysis. *Blood*, **2015**, 126, 2623-2623	2.2	
88	A New Entity of Acute Myeloid Leukemia Driven By Epigenetic and Somatic Dis-Regulation of Uncx, a Novel Homeobox Transcription Factor Gene. *Blood*, **2015**, 126, 1356-1356	2.2	
87	A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium. *Blood*, **2015**, 126, 3840-3840	2.2	
86	The Inhibition of Checkpoint Kinase 1 As a Promising Strategy to Increase the Effectiveness of Different Treatments in Acute Lymphoblastic Leukemia. *Blood*, **2015**, 126, 2478-2478	2.2	
85	Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response. *Leukemia Research*, **2014**, 38, 581-5	2.7	17
84	Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement. *Cancer*, **2014**, 120, 1002-9	6.4	92

83	A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. *Blood Cancer Journal*, **2014**, 4, e238	7	53
82	Posterior reversible encephalopathy syndrome in a B-cell acute lymphoblastic leukemia young adult patient treated with a pediatric-like chemotherapeutic schedule. *Hematology Reports*, **2014**, 6, 5565	0.9	2
81	Rationale for a pediatric-inspired approach in the adolescent and young adult population with acute lymphoblastic leukemia, with a focus on asparaginase treatment. *Hematology Reports*, **2014**, 6, 5554	0.9	8
80	Ultra-Deep Sequencing Strategy Is a Precious Tool to Find Small Clones Harbouring FLT3 Mutations in AML Patients. *Blood*, **2014**, 124, 1040-1040	2.2	2
79	Inactivation of the SETD2 Tumor Suppressor Gene in Mast Cell Leukemia. *Blood*, **2014**, 124, 1881-1881	2.2	2
78	Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome. *Blood*, **2014**, 124, 484-484	2.2	2
77	PKC412 (midostaurin) is safe and highly effective in systemic mastocytosis: Follow up of a single-center Italian compassionate use.. *Journal of Clinical Oncology*, **2014**, 32, 7113-7113	2.2	
76	SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients. *Blood*, **2014**, 124, 1030-1030	2.2	
75	Dissecting the Molecular Mechanisms of Aneuploidy in Acute Myeloid Leukemia By Next Generation Sequencing. *Blood*, **2014**, 124, 1028-1028	2.2	1
74	Backtracking BCR-ABL1 Mutants in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Relapsing on Tyrosine Kinase Inhibitors with Deep Sequencing: Implications for Routine Mutation Testing. *Blood*, **2014**, 124, 2259-2259	2.2	
73	Ultra-Deep Sequencing (UDS) Allows More Sensitive Detection of the D816V and Other Kit Gene Mutations in Systemic Mastocytosis. *Blood*, **2014**, 124, 1856-1856	2.2	
72	Next-Generation Sequencing Analysis Revealed That BCL11B Chromosomal Translocation Cooperates with Point Mutations in the Pathogenesis of Acute Myeloid Leukemia. *Blood*, **2014**, 124, 2352-2352	2.2	
71	A Survey on Clinical and Biological Characteristic and Therapy Management of an Italian Series of 455 Adult Patients with Systemic Mastocytosis on Behalf of Italian Registry of Mastocytosis. *Blood*, **2014**, 124, 3188-3188	2.2	
70	Donor Natural Killer (NK) Alloreactivity Predicts Long-Term Relapse-Free Survival in Acute Myeloid Leukemia Patients Undergoing Immunotherapy with NK Cells. *Blood*, **2014**, 124, 624-624	2.2	
69	Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. *Blood*, **2013**, 122, 1634-48	2.2	127
68	Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia. *Cancer*, **2013**, 119, 2611-9	6.4	76
67	Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin. *Pharmacogenomics Journal*, **2013**, 13, 335-41	3.5	18
66	Use of single nucleotide polymorphism array technology to improve the identification of chromosomal lesions in leukemia. *Current Cancer Drug Targets*, **2013**, 13, 791-810	2.8	9

65	Recurrent Gastrointestinal Hemorrhage in Treatment with Dasatinib in a Patient Showing SMAD4 Mutation with Acute Lymphoblastic Leukemia Philadelphia Positive and Juvenile Polyposis Hereditary Hemorrhagic Telangiectasia Syndrome. *Hematology Reports*, **2013**, 5, 26-7	0.9	6
64	A case report of acute myeloid leukemia and neurofibromatosis 1. *Hematology Reports*, **2013**, 5, 28-9	0.9	3
63	Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis. *Blood*, **2013**, 122, 2622-2622	2.2	1
62	Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy. *Blood*, **2013**, 122, 380-380	2.2	2
61	Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience. *Blood*, **2013**, 122, 3911-3911	2.2	
60	Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain. *Blood*, **2013**, 122, 3986-3986	2.2	
59	Patologic IL 17 Producing Helper T Cells In Acute Myeloid Leukemia Patients. *Blood*, **2013**, 122, 2289-2289	2.2	
58	IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. *PLoS ONE*, **2012**, 7, e40934	3.7	60
57	Cytogenetic and molecular predictors of outcome in acute lymphocytic leukemia: recent developments. *Current Hematologic Malignancy Reports*, **2012**, 7, 133-43	4.4	36
56	Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia in the ATRA and ATO era. *Haematologica*, **2012**, 97, 1731-5	6.6	18
55	Application of the whole-transcriptome shotgun sequencing approach to the study of Philadelphia-positive acute lymphoblastic leukemia. *Blood Cancer Journal*, **2012**, 2, e61	7	7
54	In Vitro and in Vivo Single-Agent Efficacy of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) Inhibitor PF-0477736 (Pfizer) in B- and T-Acute Lymphoblastic Leukemia (ALL). *Blood*, **2012**, 120, 1496-1496	2.2	3
53	Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia.. *Blood*, **2012**, 120, 2522-2522	2.2	1
52	Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse.. *Blood*, **2012**, 120, 2601-2601	2.2	4
51	Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain Allows Earlier Detection and More Accurate Characterization of Resistant Subclones in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Receiving Tyrosine Kinase Inhibitor-Based Therapies. *Blood*, **2012**, 120, 284-284	2.2	1
50	Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications. *Blood*, **2012**, 120, 692-692	2.2	1
49	PKC412 (Midostaurin) Is Safe and Highly Effective in Systemic Mastocytosis Patients: The Bologna Experience. *Blood*, **2012**, 120, 1749-1749	2.2	
48	Indoleamine 2,3-Dioxygenase (IDO) Is Associated with High Incidence of Chemorefractory Disease in Acute Myeloid Leukemia (AML) Patients. *Blood*, **2012**, 120, 4787-4787	2.2	

47	Loss of Heterozygosity At the C Wild-Type Allele of rs1042522 in the TP53 Gene Frequently Occurs During Progression of Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL).. *Blood*, **2012**, 120, 2497-2497	2.2	
46	AICDA expression in BCR/ABL1-positive acute lymphoblastic leukaemia is associated with a peculiar gene expression profile. *British Journal of Haematology*, **2011**, 152, 727-32	4.5	3
45	A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia. *Leukemia Research*, **2011**, 35, 1052-9	2.7	64
44	Patient with ataxia telangiectasia who developed acute myeloid leukemia. *Leukemia and Lymphoma* , **2011**, 52, 1818-20	1.9	6
43	CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients. *Clinical Cancer Research*, **2011**, 17, 7413-23	12.9	52
42	Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis. *Haematologica*, **2011**, 96, 552-7	6.6	64
41	Gas1 and Kif27 Genes Are Strongly up-Regulated Biomarkers of Hedgehog Inhibition (PF-04449913) on Leukemia Stem Cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia Treated Patients. *Blood*, **2011**, 118, 1535-1535	2.2	2
40	The Novel Small Molecule Chk1/Chk2 Inhibitor PF-0477736 (Pfizer) Is Highly Active As Single Agent in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). *Blood*, **2011**, 118, 76-76	2.2	1
39	TP53 Alterations Including Missense Mutations, Aberrant Exon-Junctions and Internal Intron Retentions Are Frequent and May Contribute to MDM2 Antagonist-Resistance in B-Acute Lymphoblastic leukemia. *Blood*, **2011**, 118, 1484-1484	2.2	
38	ARF Loss, a Negative Prognostic Factor in Philadelphia-Positive Acute Lymphoblastic Leukemia, May Be Efficiently Overcome by the Small Molecule MDM2 Antagonist RG7112. *Blood*, **2011**, 118, 2574-2574	2.2	
37	Different isoforms of the B-cell mutator activation-induced cytidine deaminase are aberrantly expressed in BCR-ABL1-positive acute lymphoblastic leukemia patients. *Leukemia*, **2010**, 24, 66-73	10.7	22
36	The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working Party. *Haematologica*, **2010**, 95, 1683-90	6.6	39
35	Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient. *American Journal of Hematology*, **2010**, 85, 608	7.1	20
34	Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) patient with breast infiltration. *Leukemia Research*, **2010**, 34, e246-7	2.7	4
33	B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. *Leukemia Research*, **2010**, 34, e282-5	2.7	33
32	Hydroxyurea Treatment In 1075 Patients with Essential Thrombocythemia and Occurrence of Extra-Hematological Adverse Events: A Preliminary Report of the Registro Italiano Trombocitemia (RIT). *Blood*, **2010**, 116, 1973-1973	2.2	1
31	Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen. *Blood*, **2010**, 116, 4335-4335	2.2	1
30	The Inactivation of the Tumor Suppressor Genes CDKN2A/ARF by Genomic Deletions Frequently Occurs and Worsens Prognosis In Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Patients. *Blood*, **2010**, 116, 3136-3136	2.2	

29	RASGRP1/APTX Ratio Is a Strong Biomarker of Clinical Response and Survival In AML Patients Treated with Tipifarnib: A Phase I-II Preliminary Results. *Blood*, **2010**, 116, 4359-4359	2.2	
28	Pediatric Therapy In Adult Acute Lymphoblastic Leukemia: Updated Experience of a Single Centre. *Blood*, **2010**, 116, 4338-4338	2.2	1
27	Whole Transcriptome Resequencing of Paired Diagnosis-Relapse BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL) Samples Reveals the Loss of Cell Cycle Regulation as the Main Mechanism Responsible for Leukemia Progression.. *Blood*, **2010**, 116, 1024-1024	2.2	
26	Susceptibility to Philadelphia-Positive acute Lymphoblastic Leukemia (ALL) Is Associated with a Germline Polymorphism In the ANRIL (CDKN2BAS) Locus.. *Blood*, **2010**, 116, 1670-1670	2.2	
25	Use of a High Sensitive Nanofluidic Array for the Detection of Rare Copies of BCR-ABL1 Transcript In Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (ALL).. *Blood*, **2010**, 116, 1677-1677	2.2	
24	Evaluation of the GeneXpert Assay for the Monitoring of BCR-ABL Transcript Levels In Chronic Myeloid Leukemia (CML) Patients: Preliminary Results of a Comparison with the Manual and Traditional Manual TaqMan RQ-PCR Assay. *Blood*, **2010**, 116, 4831-4831	2.2	
23	Identification of A Pharmacogenomic Profile Associated with High Sensitivity and Low Toxicity to a Combination of Gemtuzumab Ozogamicin Plus Fludarabine, Cytarabine, Idarubicin Regimen In CD33-Positive Acute Myeloid Leukemia (AML) Patients. *Blood*, **2010**, 116, 967-967	2.2	
22	Extreme Variability of FIP1L1-PDGFRalpha Transcripts In CEL: Analysis of 32 Patients Enrolled In HES0203 Italian Clinical Trial and Correlation with Clinical and Molecular Response After 5 Years Follow-up. *Blood*, **2010**, 116, 1986-1986	2.2	
21	Successful combination treatment of clofarabine, cytarabine, and gemtuzumab-ozogamicin in adult refractory B-acute lymphoblastic leukemia. *American Journal of Hematology*, **2009**, 84, 849-50	7.1	10
20	Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell@Adulto Acute Leukemia Working Party (GIMEMA AL WP). *Blood*, **2009**, 114, 2159-67	2.2	180
19	IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. *Journal of Clinical Oncology*, **2009**, 27, 5202-7	2.2	245
18	New targets for Ph+ leukaemia therapy. *Best Practice and Research in Clinical Haematology*, **2009**, 22, 445-54	4.2	11
17	Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. *Blood*, **2009**, 114, 2168-71	2.2	133
16	Four Drugs Combination (Fludarabine, Cytarabine, Idarubicin, Etoposide) as Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia Patients Younger Than 65 Ys: Response and Follow-up of 84 Patients.. *Blood*, **2009**, 114, 4147-4147	2.2	
15	PAX5 Wild-Type without IKZF1 (Ikaros) Deletion Is Associated with Prolonged Disease-Free Survival and Low Rate of Cumulative Incidence of Relapse in Adult BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL): On Behalf of GIMEMA AL Working Party.. *Blood*, **2009**, 114, 12-12	2.2	
14	RASGRP1/APTX Ratio Strongly Correlates with Clinical Response and Survival in AML Patients Treated with Tipifarnib-Bortezomib Combination.. *Blood*, **2009**, 114, 1028-1028	2.2	
13	Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia. *Hematology*, **2008**, 13, 1-12	2.2	1
12	Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute lymphoblastic leukemia by a high-throughput capillary electrophoresis sizing method. *Haematologica*, **2008**, 93, 1814-21	6.6	34

11	Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance. *Blood*, **2008**, 112, 3847-55	2.2	95
10	Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Already Harbor Bcr-Abl Kinase Domain Mutations at Low Levels at the Time of Diagnosis - a Report by the GIMEMA ALL Working Party. *Blood*, **2008**, 112, 722-722	2.2	2
9	Identification and Molecular Characterization of Two Recurrent Genomic Deletions (Type A and Type B) on 7p12 in IKZF1 Gene in a Large Cohort of BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL): on Behalf of the GIMEMA ALL Working Party. *Blood*, **2008**, 112, 428-428	2.2	
8	Induction Intensified Regimens Including Fludarabine or Mylotarg for Acute Myeloid Leukemia Patients: Comparison by Response and Follow-up.. *Blood*, **2008**, 112, 941-941	2.2	
7	Phase I/II Study of Tipifarnib and Bortezomib in the Treatment of Poor Risk Adult Acute Myeloid Leukemia. *Blood*, **2008**, 112, 2982-2982	2.2	2
6	Gemtuzumab-Ozogamicin in Combination with Fludarabine, Cytarabine, Idarubicin (FLAI-GO) as Induction Therapy in CD33-Positive AML patients Younger Than 65 Years. Report of a Multicentric Trial. *Blood*, **2008**, 112, 3998-3998	2.2	
5	Different Isoforms of the B-Cell Mutator Activation-Induced Cytidine Deaminase (AID) Are Aberrantly Over-Expressed in BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL) Patients and Promote Genetic Instability.. *Blood*, **2008**, 112, 1497-1497	2.2	
4	Myeloid sarcoma of liver: an unusual cause of jaundice. Report of three cases and review of literature. *Histopathology*, **2007**, 50, 802-5	7.3	11
3	Paraplegia due to a paravertebral extramedullary haemopoiesis in a patient with polycythaemia vera. *Journal of Clinical Pathology*, **2007**, 60, 581-2	3.9	5
2	Primary cardiac non-Hodgkin lymphoma presenting with atrial flutter and pericardial effusion. *British Journal of Haematology*, **2006**, 134, 356	4.5	8
1	NPM Mutations and Not FLT3 Mutations Are a Potential Marker for Monitoring Minimal Residual Disease in Acute Myeloid Leukemia.. *Blood*, **2006**, 108, 2016-2016	2.2	